Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRtw Biotech Regulatory News (RTW)

Share Price Information for Rtw Biotech (RTW)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.41
Bid: 1.41
Ask: 1.43
Change: 0.00 (0.00%)
Spread: 0.02 (1.418%)
Open: 1.41
High: 1.41
Low: 1.41
Prev. Close: 1.41
RTW Live PriceLast checked at -
RTW Venture is an Investment Trust

To achieve positive absolute performance and superior long-term capital appreciation, with a focus on forming, building, and supporting world-class life sciences, biopharmaceutical and medical technology companies.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison issues review on RTW Venture Fund (RTW)

20 Oct 2022 07:00

RNS Number : 4363D
RTW Venture Fund Limited
20 October 2022
 

London, UK, 20 October 2022

 

Edison issues review on RTW Venture Fund (RTW)

RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW Investments (RTW) that has offices in New York, London and Shanghai. It offers a broad range of financing options from business formations through to listed biotech and medtech companies. RTW's managers are hopeful that the performance of biotech stocks will continue to improve following a significant sell off, particularly in smaller-cap stocks, between February 2021 and May 2022. Biotech industry fundamentals and valuations are attractive, so investors with a longer-term perspective that can look through the current challenging macroeconomic backdrop may benefit from an allocation to the sector.

 

RTWVF is trading at a 20.1% discount to NAV, which is a considerably lower valuation than the average 4.1% premium since the fund was launched in October 2019. There is potential for a narrower discount if investor sentiment towards biotech stocks continues to improve and RTWVF is able to build on its longer-term positive performance record.

Click here to view the full report or here to sign up to receive research as it is published.

 

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com

Learn more at www.edisongroup.com and connect with Edison on: 

LinkedIn www.linkedin.com/company/edison-group-/

Twitter www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABBBDGCGBDGDC
Date   Source Headline
9th Feb 20247:01 amRNSTransaction in Own Shares
9th Feb 20247:00 amRNSRTW Biotech Opp. – Investment Update: Kyverna IPO
1st Feb 20247:00 amRNSTotal Voting Rights
31st Jan 20247:00 amRNSTransaction in Own Shares
30th Jan 20247:00 amRNSUpdate on Arix Transaction
24th Jan 20247:00 amRNSTransaction in Own Shares
22nd Jan 20247:00 amRNSAcacia stake purchase & capital allocation plan
18th Jan 20247:00 amRNSTransaction in Own Shares
15th Jan 20247:00 amRNSMonthly Valuation Update, December Factsheet
10th Jan 20247:00 amRNSTransaction in Own Shares
8th Jan 20249:00 amRNSInvestment Update
5th Jan 20241:00 pmRNSPublication of a Prospectus
2nd Jan 20247:00 amRNSTotal Voting Rights
14th Dec 20237:00 amRNSMonthly Valuation Update, November Factsheet
6th Dec 20237:00 amRNSTransaction in Own Shares
1st Dec 20237:01 amRNSTotal Voting Rights
1st Dec 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSPortfolio Company Update: CARGO Therapeutics, Inc
13th Nov 20237:00 amRNSTransaction in Own Shares
13th Nov 20237:00 amRNSMonthly Valuation Update, October Factsheet
9th Nov 20237:00 amRNSTransaction in Own Shares
8th Nov 20237:00 amRNSTransaction in Own Shares
1st Nov 202310:51 amEQSEdison issues flash on RTW Biotech Opportunities (RTWBIO): Significant acquisition of Arix Bioscience’s assets
1st Nov 20237:06 amRNSRTW Biotech to acquire Arix Bioscience's assets
1st Nov 20237:05 amRNSTotal Voting Rights
16th Oct 20237:00 amRNSTransaction in Own Shares
13th Oct 20237:00 amRNSMonthly Valuation Update, Sep Factsheet, Q3 Letter
3rd Oct 20234:00 pmRNSDirector Declaration
2nd Oct 20237:00 amRNSTotal Voting Rights
18th Sep 20237:00 amRNSTransaction in Own Shares
15th Sep 20237:00 amRNSMonthly Valuation Update & August Factsheet
14th Sep 20237:00 amRNSUpdate on Largest Core Portfolio Position
13th Sep 20237:00 amRNSHalf-year Report
6th Sep 20237:00 amRNSTransaction in Own Shares
4th Sep 202311:00 amRNSAdditional Investment in Portfolio Company
14th Aug 20237:00 amRNSMonthly Valuation Update & July Factsheet
4th Aug 20237:30 amRNSEdison issues update on RTW Venture Fund (RTW)
1st Aug 202312:30 pmRNSTotal Voting Rights
21st Jul 20237:00 amRNSTransaction in Own Shares
17th Jul 20237:00 amRNSPortfolio Company Update: Apogee Therapeutics IPO
17th Jul 20237:00 amRNSMonthly Valuation Update, Factsheet & Q2 Letter
5th Jul 20237:00 amRNSCapital Allocation Plans from Prometheus Sale
30th Jun 202310:00 amRNSPortfolio Company Update: Tourmaline Bio
27th Jun 20237:00 amRNSChange of Name
21st Jun 20234:22 pmRNSResult of AGM
14th Jun 20237:00 amRNSMonthly Valuation Update & Factsheet
1st Jun 20237:00 amRNSNotice of AGM
12th May 20237:00 amRNSMonthly Valuation Update & Factsheet
9th May 20237:00 amRNSPortfolio Company Update: Acelyrin IPO
2nd May 20237:00 amRNSAnnual Financial Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.